775 related articles for article (PubMed ID: 26529078)
1. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
[TBL] [Abstract][Full Text] [Related]
3. Colesevelam attenuates cholestatic liver and bile duct injury in
Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
[TBL] [Abstract][Full Text] [Related]
4. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis.
Ghallab A; González D; Strängberg E; Hofmann U; Myllys M; Hassan R; Hobloss Z; Brackhagen L; Begher-Tibbe B; Duda JC; Drenda C; Kappenberg F; Reinders J; Friebel A; Vucur M; Turajski M; Seddek AL; Abbas T; Abdelmageed N; Morad SAF; Morad W; Hamdy A; Albrecht W; Kittana N; Assali M; Vartak N; van Thriel C; Sous A; Nell P; Villar-Fernandez M; Cadenas C; Genc E; Marchan R; Luedde T; Åkerblad P; Mattsson J; Marschall HU; Hoehme S; Stirnimann G; Schwab M; Boor P; Amann K; Schmitz J; Bräsen JH; Rahnenführer J; Edlund K; Karpen SJ; Simbrunner B; Reiberger T; Mandorfer M; Trauner M; Dawson PA; Lindström E; Hengstler JG
J Hepatol; 2024 Feb; 80(2):268-281. PubMed ID: 37939855
[TBL] [Abstract][Full Text] [Related]
6. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans.
Caballero-Camino FJ; Rodrigues PM; Wångsell F; Agirre-Lizaso A; Olaizola P; Izquierdo-Sanchez L; Perugorria MJ; Bujanda L; Angelin B; Straniero S; Wallebäck A; Starke I; Gillberg PG; Strängberg E; Bonn B; Mattsson JP; Madsen MR; Hansen HH; Lindström E; Åkerblad P; Banales JM
Hepatology; 2023 Sep; 78(3):709-726. PubMed ID: 36999529
[TBL] [Abstract][Full Text] [Related]
7. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
9. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
10. Metabolic preconditioning protects BSEP/ABCB11
Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
[TBL] [Abstract][Full Text] [Related]
11. Na
Slijepcevic D; Roscam Abbing RLP; Fuchs CD; Haazen LCM; Beuers U; Trauner M; Oude Elferink RPJ; van de Graaf SFJ
Hepatology; 2018 Sep; 68(3):1057-1069. PubMed ID: 29572910
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
[TBL] [Abstract][Full Text] [Related]
14. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.
Al-Dury S; Wahlström A; Wahlin S; Langedijk J; Elferink RO; Ståhlman M; Marschall HU
Sci Rep; 2018 Apr; 8(1):6658. PubMed ID: 29704003
[TBL] [Abstract][Full Text] [Related]
15. Gut-restricted apical sodium-dependent bile acid transporter inhibitor attenuates alcohol-induced liver steatosis and injury in mice.
Matye DJ; Li Y; Chen C; Chao X; Wang H; Ni H; Ding WX; Li T
Alcohol Clin Exp Res; 2021 Jun; 45(6):1188-1199. PubMed ID: 33885179
[TBL] [Abstract][Full Text] [Related]
16. Geniposide suppresses liver injury in a mouse model of DDC-induced sclerosing cholangitis.
Wen M; Liu Y; Chen R; He P; Wu F; Li R; Lin Y
Phytother Res; 2021 Jul; 35(7):3799-3811. PubMed ID: 33763888
[TBL] [Abstract][Full Text] [Related]
17. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice.
Fickert P; Fuchsbichler A; Marschall HU; Wagner M; Zollner G; Krause R; Zatloukal K; Jaeschke H; Denk H; Trauner M
Am J Pathol; 2006 Feb; 168(2):410-22. PubMed ID: 16436656
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
[TBL] [Abstract][Full Text] [Related]
19. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
Cai SY; Yu D; Soroka CJ; Wang J; Boyer JL
J Hepatol; 2021 Mar; 74(3):550-559. PubMed ID: 33039404
[TBL] [Abstract][Full Text] [Related]
20. Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
Li J; Zhu X; Zhang M; Zhang Y; Ye S; Leng Y; Yang T; Kong L; Zhang H
J Hepatol; 2021 Aug; 75(2):400-413. PubMed ID: 33746084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
